Understand the challenges and maximize growth potential in pharmerging markets.
When you look at the numbers, there’s no question why global pharmaceutical companies have set their sights on emerging markets for future growth. From 2012 to 2017, global pharmaceutical sales are expected to rise 13% in the “pharmerging markets,” compared to 2% for the top mature markets, according to the IMS Institute for Healthcare Informatics.
Our Dealing with Uncertainty report shows that emerging markets will continue to offer the best growth in the sector but also present extra risks and uncertainties. Our survey of life sciences executives reveals the primary challenges in cross-border M&A are ensuring corporate compliance and managing regulatory uncertainty. It also provides recommendations on how companies can these risks in order to maximise returns from the growing healthcare market in developing markets.
Watch Jane Hobson, global chair of the Healthcare group, speak about the challenges when expanding into pharmerging markets.